Payment overview · 2025
General Payments
$15,409.05
87 reported records · 15 companies
Healthcare provider profile · identity verified
Amish J Desai, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · PORTLAND, OR · NPI 1134282932
Verified facts
What the public records show
CMS Open Payments records show Amish J Desai, MD received $15,409.05 in general payments during 2025 across 87 reported records.
Boston Scientific Corporation accounted for 86.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $13,333.07 | 86.5% | 31 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $864.03 | 5.6% | 25 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $430.92 | 2.8% | 11 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $220.91 | 1.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $208.42 | 1.4% | 5 | 2025 |
| ENDOTRONIX, INC. | Unresolved — no canonical attribution shown | $83.17 | 0.5% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $53.94 | 0.3% | 1 | 2025 |
| Acist Medical Systems, Inc. | Unresolved — no canonical attribution shown | $37.57 | 0.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $33.27 | 0.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.61 | 0.2% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $27.95 | 0.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.93 | 0.2% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $21.57 | 0.1% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $21.48 | 0.1% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $14.21 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,500.00 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,500.00 | 2 |
| Food and Beverage | $3,311.05 | 82 |
| Travel and Lodging | $98.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $7,854.21 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $4,575.36 | 4 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $424.98 | 17 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $411.62 | 7 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $220.91 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $191.73 | 3 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $183.02 | 3 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $147.95 | 3 | 2025 |
Source payment records
|
|||||
| VersaCross Steerable Access Solution Normalized: versacross steerable access solution |
Device | Boston Scientific Corporation | $141.32 | 4 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $111.86 | 3 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $110.87 | 2 | 2025 |
Source payment records
|
|||||
| CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Normalized: cordella pulomonary artery pressure sensor |
Device | ENDOTRONIX, INC. | $83.17 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Large Access Solution Normalized: versacross large access solution |
Device | Boston Scientific Corporation | $74.74 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $53.94 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $43.75 | 1 | 2025 |
Source payment records
|
|||||
| CVI Systems Normalized: cvi systems |
Device | Acist Medical Systems, Inc. | $37.57 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $31.61 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $31.07 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY Normalized: synergy |
Device | Boston Scientific Corporation | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 53 | 30 |
| Eliquis | Apixaban | 42 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,409.05 · 87 records | Boston Scientific Corporation | AMPLATZER AMULET, AVVIGO Guidance System, CORDELLA PULOMONARY ARTERY PRESSURE SENSOR, CVI Systems, FARAPULSE, FFRct, GORE CARDIOFORM Septal Occluder, GUIDELINER, General - Therapies, LifeVest, MITRACLIP, MYNX CONTROL VENOUS, NAVITOR, PASCAL, Paradise Ultrasound Renal Denervation System, ROTAPRO, SAPIEN 3 Ultra RESILIA, SYNERGY, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRICLIP, VERQUVO, VersaCross Access Solution, VersaCross Large Access Solution, VersaCross Steerable Access Solution, WATCHMAN Access System, WATCHMAN FLX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error